Project Grant R03CA241784

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $994,859 to Cytoagents Inc. to develop the compound CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. Cytoagents is conducting a Phase 1b clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of CTO1681 in reducing CRS and immune effector cell-associated neurotoxicity...

This $4,753,460 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a randomized Phase 2 clinical trial evaluating the PI3KD inhibitor roginolisib in combination with venetoclax and rituximab for the treatment of relapsed chronic lymphocytic leukemia (CLL) patients. The study will be conducted by the Dana-Farber Cancer Institute, Inc. (DFCI), a prestigious non-profit cancer research center in Boston, Massachusetts....

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,283,068 to Washington University to develop and evaluate next-generation radioimmunotherapies for non-Hodgkin lymphoma. The 5-year project aims to create precision radiopharmaceutical therapies using single-agent and combination regimens of B-particle (Lu177) and A-particle (Ac225, Pb212, Th227) emitting anti-CD20 antibodies in preclinical models. It will also assess a...

This Project Grant award, valued at $678,101, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The funding supports a 5-year research project to develop a novel radioimmunotherapy targeting the active conformation of integrin beta-2 as a potential best-in-class treatment for acute myeloid leukemia (AML). The key objectives are to: 1) evaluate the preclinical efficacy...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $635,248 to Trustees of Boston University to develop a novel self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T cell engager (BITE) antibody for the treatment of lung cancer. The key goals are to: Design 5-methylcytidine (5MC) modified SARNA constructs encoding BITE antibodies and evaluate their protein expression performance in vitro. Assess the in vitro and in...

This $256,000 National Science Foundation project grant supports the generation of directly active monoclonal antibodies to CD19 for the treatment of B-cell malignancies by Welt Bio-Molecular Pharmaceutical, LLC. The grant funds research under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop novel monoclonal antibody therapies that could provide more affordable and less toxic options for leukemias and lymphomas compared to current drugs. Specifically, the awardee...

The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...

This $1,398,552 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Avantgen Inc., a San Diego-based biotechnology company, in conducting preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The key products and services to be delivered under this grant include cell line development, early chemistry and manufacturing controls (CMC)...

The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $3,157,784 Project Grant to Synthis Therapeutics, Inc. to conduct in vivo efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) analysis of SYN101, a first-in-class immune cell-targeted TGFβ therapy for cancer patients. The goals of the 22-month project are to: 1) test the efficacy of SYN101 in humanized mouse tumor models and define the comprehensive immune response, and...

The National Cancer Institute (NCI) awarded a $2,000,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Sonoval LLC, a for-profit limited liability company located in Baltimore, MD. The purpose of this 2-year grant, which runs from August 2024 to July 2026, is to develop a second-generation version of the TREG-depleting immunotherapy ONTAK, called SON-211. Sonoval aims to eliminate the vascular leak syndrome side effect that led to ONTAK's removal from the market, while retaining its...